Fate Therapeutics is a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. The company positions its pipeline around off-the-shelf NK and T-cell product candidates built on a proprietary iPSC platform. It is headquartered in San Diego and publicly traded on Nasdaq under FATE.
The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07570862 |
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07560865 |
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma |
RECRUITING | PHASE1 |
| NCT07216105 |
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06308978 |
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease |
RECRUITING | PHASE1 |
| NCT06241456 |
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT05950334 |
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) |
COMPLETED | PHASE1 |
| NCT05934097 |
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma |
WITHDRAWN | PHASE1 |
| NCT05395052 |
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors |
TERMINATED | PHASE1 |
| NCT05182073 |
FT576 in Subjects With Multiple Myeloma |
COMPLETED | PHASE1 |
| NCT05069935 |
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors |
TERMINATED | PHASE1 |
